330786-25-9
基本信息
4-氨基-1-环戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶
PCI 29732
PCI 29732
PCI29732
PCI-29732
PCI 29732 (This product is only available in Japan.)
1-Cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
4-Amino-1-cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine
1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-cyclopentyl-3-(4-phenoxyphenyl)-
物理化学性质
沸点 | 599.6±50.0 °C(Predicted) |
密度 | 1.36±0.1 g/cm3(Predicted) |
储存条件 | -20°C储存 |
溶解度 | DMF: 20 mg/ml; DMF:PBS (pH 7.2) (1:2): 0.3 mg/ml; DMSO: 10 mg/ml; Ethanol: 5 mg/ml |
酸度系数(pKa) | 4.24±0.30(Predicted) |
形态 | 粉末 |
颜色 | White to off-white |
安全数据
危险性符号(GHS) | GHS07 |
警示词 | 警告 |
危险性描述 | H302-H315-H319-H335 |
防范说明 | P261-P305+P351+P338 |
4-氨基-1-环戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/11/08 | HY-18010 | 4-氨基-1-环戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶 PCI 29732 | 330786-25-9 | 5mg | 1000元 |
2024/11/08 | HY-18010 | 4-氨基-1-环戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶 PCI 29732 | 330786-25-9 | 10mM * 1mLin DMSO | 1100元 |
2024/11/08 | HY-18010 | 4-氨基-1-环戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶 PCI 29732 | 330786-25-9 | 10mg | 1600元 |
常见问题列表
Target | Value |
BTK
(Cell-free assay) | 0.5 nM |
BLK
(Cell-free assay) | 0.5 nM |
Bmx
(Cell-free assay) | 0.8 nM |
EGFR
(Cell-free assay) | 5.6 nM |
YES
(Cell-free assay) | 6.5 nM |
PCI29732 shows cytotoxicity in different cells. The IC
50
values are 7.94 μM for S1, 7.79 μM for S1-MI-80, 6.55 μM for H460, 6.34 μM for H460/MX20, 6.14 μM for KB, 6.02 μM for KBv200, 12.45 μM for HEK293/pcDNA3, 14.58 μM for HEK293-ABCG2-482-R2, and 13.24 μM for HEK293-ABCG2-482-T7 cells.
PCI-29732 blocks the transcriptional up-regulation of a panel of B-cell activation genes in human CD20+ B cells stimulated at the B-cell antigen receptor (BCR).
PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 and enhances the anti-tumor efficacy of substrate chemotherapeutic agents.
PCI 29732 (20 mg/kg; p.o.; every 3 d × 5 times) enhances the anticancer efficacy of Topotecan in the H460/MX20 cell xenograft nude mice model.
Animal Model: | 5-6 weeks old athymic nude mice (bearing H460/MX20 cells) |
Dosage: | 20 mg/kg (combination with Topotecan; every 3 d × 5 times, i.p., 3 mg/kg; topotecan was given 1 h after PCI29732 administration) |
Administration: | P.o.; every 3 d × 5 times |
Result: | Significant reductions in tumor weight and volume were observed in the group treated with PCI29732 in combination with Topotecan. |